Sandra Horning, MD
The addition of atezolizumab (Tecentriq) to bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer (NSCLC), according to topline findings from the phase III IMpower150 trial released by Roche, the manufacturer of the anti–PD-L1 and anti–VEGF agents.
For the interim analysis, the study was only designed to compare arms B and C. In addition to the co-primary endpoints, the study also assed objective response rates and safety. The company noted there were no unexpected adverse events in the study and that each of the agents showed similar toxicity profiles as in other trials.
... to read the full story